Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Carfilzomib - Onyx Pharmaceuticals

Drug Profile

Carfilzomib - Onyx Pharmaceuticals

Alternative Names: Kyprolis; ONO-7057; PR-171

Latest Information Update: 14 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Proteolix
  • Developer AbbVie; Dana-Farber Cancer Institute; Genentech; Janssen Biotech; M. D. Anderson Cancer Center; Ohio State University Comprehensive Cancer Center; Ono Pharmaceutical; Onyx Pharmaceuticals; Phoenix Children's Hospital; Roswell Park Cancer Institute; The Innovative Therapies for Children with Cancer; Therapeutic Advances in Childhood Leukemia & Lymphoma; University of Alabama at Birmingham; University of Birmingham; University of California, Davis; University of Rochester; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Epoxy compounds; Oligopeptides; Small molecules
  • Mechanism of Action Proteasome inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma; Waldenstrom's macroglobulinaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes - Multiple myeloma

Highest Development Phases

  • Marketed Multiple myeloma
  • Phase II Mantle-cell lymphoma; Prostate cancer; Renal cell carcinoma; Waldenstrom's macroglobulinaemia
  • Phase I/II Diffuse large B cell lymphoma; Peripheral T-cell lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Small cell lung cancer; Solid tumours
  • No development reported Leukaemia; Lymphoid leukaemia; Lymphoma; Systemic lupus erythematosus

Most Recent Events

  • 14 Nov 2019 9278818: Info already covered
  • 31 Oct 2019 Carfilzomib licensed to BeiGene in China
  • 28 Oct 2019 Amgen completes a phase Ib trial in Multiple myeloma (Combination therapy, Newly diagnosed, Second-line therapy or grater) in USA (IV) (NCT02335983)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top